Saturday 17 October 2026 Export ALC’s income statement to Excel — free account

Alcon

ALC Healthcare Medical Instruments & Supplies

Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS fell 100.0%, free cash flow was flat and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

66.18 0.40 −0.60%

Follow ALC

Alert me

Market cap: $32.1B
P/E: 50.5×
Fwd P/E: 31.0×
Dividend yield: 0.53%
F-score: 6/9
Altman Z: n/a
Beneish M: −2.56
Dividend safety: 66/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.05%

Capital & Financial Ratios $m

Market Cap 32,100.00

Revenue 10,861.00

Net Income 643.00

Free Cash Flow 1,594.00

Net Debt 3,263.00

Current Ratio 2.09

Debt/Equity 0.22

P/E ratio 50.52

Fwd P/E 31.00

P/S ratio 2.97

P/B ratio 1.49

Past 5Y EPS Growth —

This Y EPS Growth 13.67%

Next Y EPS Growth 13.07%

Next Y revenue growth (25.94%)

Next 5Y EPS Growth 13.28%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 49.64%

10-year low 10-year high

P/S against its own 10 years 1.96%

10-year low 10-year high

P/B against its own 10 years 15.96%

10-year low 10-year high

EV/Sales against its own 10 years 1.91%

10-year low 10-year high

EV/FCF against its own 10 years 2.54%

10-year low 10-year high

Dividends

Payout Ratio 0.27

Annual Dividend Rate 0.35

Annual Dividend Yield 0.53%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.26	0.35
2025	0.23	0.33
2024	0.54	0.27 0.26
2023	0.24	0.24
2022	0.20	0.20
2021	0.21	0.10 0.11

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,094	1,829	1,607	1,456
Receivables	1,804	1,759	1,962	2,100
Inventory	2,322	2,268	2,391	2,510
Other	427	453	489	558
	5,647	6,309	6,449	6,624

	2023	2024	2025	Q'26
Payables	811	773	926	968
ST’ Debt	63	105	575	570
Other	1,339	1,228	1,286	1,320
	2,398	2,278	3,049	3,167

Compound Annual Growth %

	10y	5y	3y
Sales	—	8.77%	6.06%
Cash Flow	—	22.51%	23.11%
Earnings	—	0.00%	43.02%
Book Value	—	3.20%	3.84%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2,706	2,823	—	—	—
’25	2,473	2,596	2,614	2,718	10,401
’24	2,459	2,496	2,454	2,502	9,911
’23	2,352	2,422	2,329	2,352	9,455
’22	2,189	2,217	2,140	2,171	8,717
’21	1,930	2,110	2,102	2,149	8,291
’20	1,841	1,214	1,838	1,940	6,833

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	418	510	—	—	—
’25	384	505	724	658	2,271
’24	341	530	747	459	2,077
’23	85	325	527	451	1,388
’22	66	404	402	345	1,217
’21	156	386	416	387	1,345
’20	30	28	326	439	823

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	227	370	—	—	—
’25	244	372	540	457	1,613
’24	198	410	570	229	1,407
’23	(44)	101	378	102	537
’22	(64)	274	172	90	472
’21	34	(125)	214	42	165
’20	(74)	(68)	199	205	262

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.39	0.00	—	—	—
’25	0.70	0.35	0.48	0.44	1.98
’24	0.50	0.45	0.53	0.57	2.05
’23	0.35	0.34	0.41	0.86	1.96
’22	0.34	0.30	0.23	(0.20)	0.68
’21	0.17	0.31	0.00	0.28	0.76
’20	(0.12)	(0.86)	(0.30)	0.19	(1.09)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	53.78	39.37	64.83	55.21	63.78	74.30	71.55	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	63.73	68.11	88.78	87.34	86.20	101.10	99.20
People
People	Employees	—	—	—	22,142	23,655	24,389	25,000	25,000	25,599	25,942
	Revenue/emp, $m	0.00	0.00	0.00	0.34	0.29	0.34	0.35	0.38	0.39	0.40
Income, $m
Income, $m	Revenue	6,371	6,821	7,153	7,508	6,833	8,291	8,717	9,455	9,911	10,401
	Gross margin, %	47.17	47.18	44.62	48.77	43.03	56.11	54.47	55.49	55.61	55.24
	EBT	(109)	(128)	(300)	(332)	(635)	418	463	832	1,256	1,160
	EBT margin, %	(1.71)	(1.87)	(4.19)	(4.42)	(9.29)	5.04	5.31	8.80	12.67	11.15
	Net income	(164)	0	(227)	(656)	(531)	376	335	974	1,018	980
	Depreciation	1,245	1,310	1,622	1,456	1,626	1,220	1,111	1,226	1,226	1,191
Per share, $
Per share, $	Revenue	0.00	13.95	14.65	15.38	13.97	16.92	17.74	19.18	20.05	21.09
	Earnings	(0.33)	0.53	(0.46)	(1.34)	(1.09)	0.77	0.68	1.98	2.06	1.99
	Cash flow	0.00	2.50	2.34	1.88	1.68	2.74	2.48	2.82	4.20	4.60
	Capex	0.00	0.00	(1.46)	(1.38)	(1.15)	(2.41)	(1.52)	(1.73)	(1.36)	(1.33)
	Free cash flow	0.00	2.50	0.88	0.50	0.54	0.34	0.96	1.09	2.85	3.27
	Book value	0.00	46.83	46.37	39.54	38.49	39.30	40.04	41.83	43.59	44.68
	Shares, m	0	489	488	488	489	490	491	493	494	493
Valuation, ×
Valuation, ×	P/E	0.00	21.68	0.00	0.00	0.00	114.02	101.44	39.11	41.41	39.60
	P/S	0.00	0.00	0.00	3.68	4.72	5.15	3.89	4.02	4.23	3.74
	P/B	1.25	1.25	1.25	1.43	1.71	2.22	1.72	1.84	1.95	1.76
	EV/Sales	0.00	0.00	0.00	4.03	5.10	5.45	4.31	4.40	4.52	4.04
	EV/FCF	51.63	51.63	51.63	124.08	132.92	273.90	79.59	77.52	31.83	26.04
Cash, $m
Cash, $m	Operating cash flow	1,203	1,223	1,140	920	823	1,345	1,217	1,388	2,077	2,271
	Capex	(522)	(614)	(712)	(676)	(561)	(1,180)	(745)	(851)	(670)	(658)
	Free cash flow	1,203	1,223	428	244	262	165	472	537	1,407	1,613
Balance, $m
Balance, $m	Working capital	1,349	1,500	1,506	1,936	2,729	2,914	2,455	3,249	4,031	3,400
	Total debt	248	148	137	3,479	4,118	4,080	4,648	4,739	4,643	4,737
	Net debt	86	(23)	(90)	2,657	2,561	2,505	3,668	3,645	2,814	3,130
	Shareholders’ equity	22,929	22,900	22,639	19,303	18,822	19,256	19,677	20,624	21,553	22,035
Returns, %
Returns, %	ROA	(0.60)	1.86	(0.83)	(2.40)	(1.92)	1.35	1.17	3.31	3.40	3.17
	ROIC	0.00	0.00	(0.69)	(0.53)	(1.41)	1.67	1.80	2.68	3.62	3.38
	ROE	(0.71)	1.12	(1.00)	(3.13)	(2.79)	1.97	1.72	4.83	4.83	4.50

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BDX Becton, Dickinson and Company	$52.8B	57.8×	37.7×	+5.44% (above 0%: growing)	−31.50% (below 0%: shrinking)	−31.57% (below 0%: shrinking)	46.46%	13.31%	Compare
MDLN Medline Inc.	$48.1B	—	—	+15.67% (above 0%: growing)	—	+3.42% (above 0%: growing)	28.82%	5.14%	Compare
RMD ResMed Inc.	$34.1B	22.8×	16.6×	+8.58% (above 0%: growing)	+2.32% (above 0%: growing)	−21.31% (below 0%: shrinking)	58.84%	30.66%	Compare
ALC Alcon	$32.1B	50.5×	31.0×	+8.74% (above 0%: growing)	n/m	−0.54% (below 0%: shrinking)	59.33%	0.39%
WST West Pharmaceutical Services, Inc.	$27.0B	48.7×	37.3×	+13.80% (above 0%: growing)	+19.23% (above 0%: growing)	−20.71% (below 0%: shrinking)	37.74%	20.53%	Compare
SOLV Solventum Corporation	$15.0B	10.4×	39.0×	+2.22% (above 0%: growing)	+1.92% (above 0%: growing)	+144.07% (above 0%: growing)	58.22%	8.19%	Compare
BAX Baxter International Inc.	$13.3B	— (loss-making)	44.7×	+5.34% (above 0%: growing)	+33.33% (above 0%: growing)	+119.48% (above 0%: growing)	34.86%	7.33%	Compare
RGEN Repligen Corporation	$11.7B	234×	112×	+11.93% (above 0%: growing)	−65.38% (below 0%: shrinking)	+27.10% (above 0%: growing)	53.91%	6.85%	Compare
COO The Cooper Companies, Inc.	$10.9B	19.8×	28.7×	+0.56% (above 0%: growing)	+357.14% (above 0%: growing)	+65.96% (above 0%: growing)	66.77%	20.82%	Compare
Median of peers	$21.0B	35.8×	37.7×	+7.01%	+2.32%	+15.26%	50.19%	10.75%

All 55 Medical Instruments & Supplies stocks →

Alcon (ALC) key facts

Strength: Alcon’s revenue for fiscal 2025 (year ended December 2025) was $10.4 billion, up 4.94% from fiscal 2024.
Alcon (ALC) is a Medical Instruments & Supplies company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, ALC traded at $66.18, a market capitalization of $32.1 billion.
Alcon pays an annual dividend of $0.35 per share, a yield of 0.53%, with a payout ratio of 26.8%.
Return on equity was 4.50% and debt-to-equity 0.22.
Its Piotroski F-score is 6 out of 9 for fiscal 2025.